Scholarlink

Objectives <p>To explore the potential impact of the coronavirus disease 2019 (COVID-19) pandemic on the epidemiology of small-cell lung cancer (SCLC).</p> Methods <p>SCLC patients were collected from the Surveillance, Epidemiology, and End-Results (SEER) database (diagnosed between 2018 and 2021) and grouped according to the timing of the COVID-19 pandemic. Intergroup comparisons and survival analyses were performed on clinicopathologic characteristics and survival data to explore the differences in morbidity characteristics and survival in SCLC patients before and after the pandemic.</p> Results <p>SCLC Patients diagnosed in the post-COVID-19 pandemic tended to have earlier tumor stage, receive chemotherapy (OR 1.14, 95% CI 1.02–1.27, P-value = 0.02) rather than radiotherapy (OR 0.89, 95% CI 0.84–0.96, P-value &lt; 0.01), and have increased time to treatment delay. Balancing follow-up time and constructing improved survival curves, patients with SCLC diagnosed after the pandemic tended to have a worse prognosis.</p> Conclusions <p>Differences in some clinicopathologic factors and treatment choices, or the pandemic itself, may result in a tendency for patients with SCLC diagnosed after the pandemic to have a worse prognosis, alerting clinicians to the need to focus on the management and treatment of this population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The impact of the COVID-19 pandemic on the small cell lung cancer epidemiology

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月9日

查看全文
  • Xuemei Zhang,
  • Lele Chang,
  • Wansu Xu

摘要

Objectives

To explore the potential impact of the coronavirus disease 2019 (COVID-19) pandemic on the epidemiology of small-cell lung cancer (SCLC).

Methods

SCLC patients were collected from the Surveillance, Epidemiology, and End-Results (SEER) database (diagnosed between 2018 and 2021) and grouped according to the timing of the COVID-19 pandemic. Intergroup comparisons and survival analyses were performed on clinicopathologic characteristics and survival data to explore the differences in morbidity characteristics and survival in SCLC patients before and after the pandemic.

Results

SCLC Patients diagnosed in the post-COVID-19 pandemic tended to have earlier tumor stage, receive chemotherapy (OR 1.14, 95% CI 1.02–1.27, P-value = 0.02) rather than radiotherapy (OR 0.89, 95% CI 0.84–0.96, P-value < 0.01), and have increased time to treatment delay. Balancing follow-up time and constructing improved survival curves, patients with SCLC diagnosed after the pandemic tended to have a worse prognosis.

Conclusions

Differences in some clinicopathologic factors and treatment choices, or the pandemic itself, may result in a tendency for patients with SCLC diagnosed after the pandemic to have a worse prognosis, alerting clinicians to the need to focus on the management and treatment of this population.